A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy-Reference-Cited by-同舟云学术

A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy

Published:2019-08-07 Issue:2 Volume:178 Page:337-345
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Robinson Andrew,Stober Carol,Fergusson Dean,Kehoe Anne,Bedard Debbie,MacDonald Fiona,Brunet Marie-Claude,Saunders Deanna,Mazzarello Sasha,Vandermeer Lisa,Joy Anil A.,Awan Arif,Basulaiman Bassam,Mallick Ranjeeta,Hutton Brian,Clemons Mark^ORCID,

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-019-05388-5.pdf

Reference18 articles.

1. Lipitz-Snyderman A et al (2015) Complications associated with use of long-term central venous catheters among commercially insured women with breast cancer. J Oncol Pract 11(6):505–510

2. Chopra V et al (2013) Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet 382(9889):311–325

3. LeVasseur N et al (2018) Optimizing vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer-a survey of oncology nurses and physicians. Curr Oncol 25(4):e298–e304

4. LeVasseur N et al (2018) Perceptions of vascular access for intravenous systemic therapy and risk factors for lymphedema in early-stage breast cancer—a patient survey. Curr Oncol 25(4):e305–e310

5. Krein SL et al (2019) Patient-reported complications related to peripherally inserted central catheters: a multicentre prospective cohort study. BMJ Qual Saf 28(7):574

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular access device type for systemic anti-cancer therapies in cancer patients: A scoping review;Critical Reviews in Oncology/Hematology;2024-04

2. The global patent landscape of HER2-targeted biologics;Nature Biotechnology;2023-06

3. Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program;Current Oncology;2022-12-05

4. Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective;Current Oncology;2022-06-06

5. The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design;Current Oncology;2021-10-04